Company: NCEL
Filing Date: 2025-06-23
Form Type: F-4/A
Source: 0001213900-25-056787
Chunk: 442

Company: NewcelX Ltd.
Filing Date: 2025-06-23
Form: F-4/A
Chunk 442
---
 Galili has served as a director at Kadimastem since July 2021. Ms. Galili has three decades of experience in various management positions in the pharmaceutical space. Ms. Galili served as the CEO of Ilex Medical Ltd. from January 2016 to October 2024, and she previously served as the company’s Deputy CEO in January 2014, and Vice President of Sales and Marketing from January 2010 to December 2013. Ms. Galili has an MBA in Healthcare Innovation from Reichman University, Herzliya, Israel, and a B.A. in Philosophy and History of the Middle East in Modern Times from Tel Aviv University, Israel. Family Relationships Mr.Ariel Revel, Director of Medical Affairs of the combined company, is the son of Professor Michel Revel, Chief Scientific Officer and director of the combined company. Director Independence Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren are the independent directors of Kadimastem. The Kadimastem Board has determined that all of its current independent directors are independent, as determined in accordance with the rules of The Nasdaq Stock Market. Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren as members of each of the Audit, Compensation, Nomination and Governance Committees for a term lasting until the next annual ordinary shareholders’ meeting. The Kadimastem Board has also determined that each current member of the compensation committee is independent as defined under Nasdaq listing standards and the Israel Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq listing standards and applicable SEC rules and Israel Companies laws. 252 Board Committees Mr.Olivier Samuel, Mr.Eran Iohan and Ms. Liora Oren as members of each of the Audit, Compensation, Nomination and Governance Committee for a term lasting until the next annual ordinary shareholders’ meeting. The Kadimastem Board has determined that each current member of the compensation committee is independent as defined under Nasdaq listing standards and the Israel Companies Law, and that each current member of the audit committee is independent as defined under Nasdaq listing standards and applicable SEC rules and Israel Companies laws. Audit Committee The audit committee of NLS, or the Audit Committee, focuses on financial reporting integrity, oversight of auditors, internal controls, and risk/compliance. It provides an independent check on NLS’s accounting and financial practices, reporting regularly to the NLS Board on these matters. The Audit Committee